Immunogenicity induced by passively applied proteins is a serious issue because it is directly related to the patient's safety. The out-come of an immune reaction to a therapeutic protein can range from transient appearance of antibodies without any clinical significance to severe life threatening conditions. Within this article, enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) methodology to measure immunogenicity are compared and the pros and cons are discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2009.07.013 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!